Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

AxoGen's top line has sustained growth near 23% to 27% over the last three quarters, reaching $75.8M in 2026Q3, and its gross margin of roughly 72% to 77% suggests the proprietary processing advantage remains intact as volume scales.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $0.21+59.9% vs $0.13 | $76M+3.2% vs $73M |
Q3 2026 Jul 29, 2026 | $0.12-1.2% vs $0.12 | $70M+3.9% vs $67M |
Q2 2026 Apr 28, 2026 | $0.07-41.7% vs $0.12 | $61M+6.2% vs $58M |
Q1 2026 Feb 24, 2026 | $0.07-21.2% vs $0.09 | $60M+1.5% vs $59M |
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?
Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth, and operating leverage outpacing dilution, with guidance for at least $290M in 2026 sales and 73%+ gross margin. The $200M BioCircuit (NerveTape) acquisition eliminates technical barriers for surgeons, expands the addressable market, and is accretive at 5.9x expected 2027 sales.
Benchmark AXGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AxoGen, Inc. (AXGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $56.95 | $3.06B | -109.77 | 20.21% | -11.96% | -11.34% | — | |
| $0.78 | $34.9M | -1.07 | 15.84% | -53.57% | — | — | |
| $10.73 | $1.24B | -10.29 | 8.28% | -16.78% | -35.81% | — | |
| $0.21 | $28.87M | 6.86 | 14.21% | -15.92% | -36.21% | — | |
| $3.18 | $463.52M | -24.16 | 19.99% | -6.32% | -8.29% | — | |
| $13.62 | $182.28M | -103.26 | -5.91% | -1.43% | -1.28% | — |
AxoGen, Inc. (AXGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AxoGen, Inc. (AXGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Oct 1, 2026·SEC
Jul 29, 2026·SEC
Get notified when AXGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AxoGen, Inc. (AXGN) stock FAQ — growth, dividends, profitability & financials explained
AxoGen, Inc. (AXGN) reported $266.9M in revenue over the trailing twelve months. Revenue was $225.2M in fiscal year 2025. That is 1619% more than the $13.1M of fiscal year 1996.
AxoGen, Inc. (AXGN) grew revenue by 24.3% over the trailing twelve months, compared with the twelve months before.
No. AxoGen, Inc. (AXGN) reported a net loss of $31.9M over the trailing twelve months.
AxoGen, Inc. (AXGN) had a return on equity (ROE) of -11.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
AxoGen, Inc. (AXGN) generated $16.3M in free cash flow over the trailing twelve months.